MSD Animal Health Receives Positive Final Opinion from European Medicines Agency for BRAVECTO™ (fluralaner) Spot-On for Cats and Dogs
Dateline City:
MADISON, N.J.
Only Spot-On Treatment for Fleas and Ticks Effective For 12 Weeks
MADISON, N.J.--(BUSINESS WIRE)--MSD Animal Health (known as Merck Animal Health in the United States and
Canada) today announced that the Committee for Medicinal Products for
Veterinary Use (CVMP) of the European Medicines Agency has adopted a
positive final opinion, recommending the granting of a marketing
authorization for the veterinary medicinal product BRAVECTO™
(fluralaner) Spot-On for both cats and dogs.
Language:
English
Contact:
MSD Animal HealthMedia:Amy Firsching, +1-908-473-6357amy.firsching@merck.comorPam Eisele, +1-908-423-5042pamela_eisele@merck.com
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News Source Type: news
More News: European Medicines Agency (EMA) | Health | Marketing | Merck | Pharmaceuticals | Veterinary Research